Literature DB >> 8551612

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

T M Richardson1, B L Stryjewski, C C Broder, J A Hoxie, J R Mascola, P L Earl, R W Doms.   

Abstract

The humoral immune response to human immunodeficiency virus type 1 (HIV-1) is often studied by using monomeric or denatured envelope proteins (Env). However, native HIV-1 Env complexes that maintain quaternary structure elicit immune responses that are qualitatively distinct from those seen with monomeric or denatured Env. To more accurately assess the levels and types of antibodies elicited by HIV-1 infection, we developed an antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. We compared the reactivities of clade B and clade E serum samples to captured Env preparations and found that while both reacted equally well with oligomeric gp140, clade B seras reacted more strongly with monomeric gp120 than did clade E samples. However, these differences were minimized when gp120 was captured by a V3 loop MAb, which may lead to increased exposure of the CD4 binding site. We also measured the ability of serum samples to block binding of MAbs to epitopes in gp120 and gp41. Clade B serum samples consistently blocked binding of oligomer-dependent MAbs to gp41 and, to a slightly lesser extent, MAbs to the CD4 binding site in gp120. Clade E serum samples showed equivalent or greater blocking of oligomer-dependent gp41 antibodies and considerably less blocking of CD4-binding-site MAbs. Finally, we found that < 5% of the antibodies in clade B sera bound to epitopes present only in monomeric gp120, 30% bound to epitopes present in both monomeric gp120 and oligomeric gp140, and 70% bound to epitopes present in oligomeric gp140, which includes gp41. Thus, captured oligomeric Env closely reflects the antigenic characteristics of Env protein on the surface of virions and infected cells, retains highly conserved epitopes that are recognized by antibodies raised against different clades, and makes it possible to detect a much greater fraction of total anti-HIV-1 Env activity in sera than does native monomeric gp120.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551612      PMCID: PMC189876     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Protein oligomerization in the endoplasmic reticulum.

Authors:  S M Hurtley; A Helenius
Journal:  Annu Rev Cell Biol       Date:  1989

2.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Authors:  P Poumbourios; W el Ahmar; D A McPhee; B E Kemp
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.

Authors:  E L Delwart; E G Shpaer; J Louwagie; F E McCutchan; M Grez; H Rübsamen-Waigmann; J I Mullins
Journal:  Science       Date:  1993-11-19       Impact factor: 47.728

5.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

Authors:  C C Broder; P L Earl; D Long; S T Abedon; B Moss; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

7.  Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.

Authors:  M Groenink; J P Moore; S Broersen; H Schuitemaker
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.

Authors:  M K Gorny; J P Moore; A J Conley; S Karwowska; J Sodroski; C Williams; S Burda; L J Boots; S Zolla-Pazner
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more
  34 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors:  H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

7.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

8.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

9.  Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response.

Authors:  Danielle B Ulanet; Michael Torbenson; Chi V Dang; Livia Casciola-Rosen; Antony Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

10.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.